Vaxinano

Vaxinano is a French clinical-stage biotechnology company focused on developing next-generation nasal vaccines for both human and animal health. The company aims to combat infectious diseases, including pandemics, parasites, viruses, and bacteria. Founded in France, Vaxinano employs between 11 to 50 people and is dedicated to transforming the vaccination market with innovative, easy-to-administer solutions that can be used at home and deployed globally.

The company's proprietary STELLAR-NP™ muco-adhesive nanoparticle platform enables the creation of stable, adjuvant-free, thermostable formulations for needle-free intranasal or oral administration. This technology eliminates the need for cold-chain storage, making vaccines more accessible in regions with limited infrastructure. Vaxinano's core technology converts traditional injectable vaccines into effective nasal or oral versions, providing strong immune responses against difficult pathogens. The company is actively advancing its flagship vaccines and has recently out-licensed a product targeting leishmaniasis.